New Drug application made by MD Anderson Cancer Center for a Phase I trial of the Company’s licensed drug compound WP1066 has been allowed by the U.S. Food and Drug Administration

On November 29, 2017, Moleculin Biotech, Inc. (the "Company") was informed that the physician-sponsored Investigational New Drug application made by MD Anderson Cancer Center for a Phase I trial of the Company’s licensed drug compound WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma has been allowed by the U.S. Food and Drug Administration (Press release, Moleculin, DEC 4, 2017, View Source [SID1234522355]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!